Loading market dashboard
CAMP4 Therapeutics Corporation
CAMPHealthcareNASDAQUS
Loading disclosure news
News and disclosures filtered by period, publisher, and event group.
Select a headline to open the full news page in the app.
Company to advance NI 43-101 Technical Report; 2026 exploration campaign to follow up on promising historic work including high-grade intercepts of 5.6 metres of 4.87 g/t gold Vancouver, British Columbia, TheNewswire, May 26, 2026, Canadian GoldCamps Corp. (CSE: CAMP) (OTC: SMATF) (FSE: A68) is pleased to provide an update on its 2026 exploration strategy for the Mercator and Courcy gold projects located in the Caniapiscau district of northeastern Québec.
CAMBRIDGE, Mass., May 21, 2026 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation (“CAMP4” or “the Company”) (Nasdaq: CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targeting therapeutics designed to upregulate gene expression with the goal of restoring healthy protein levels to treat a broad range of genetic diseases, today announced that on May 15, 2026 (the “Grant Date”), the Compensation Committee of the Company's Board of Directors granted a non-qualified stock option to purchase 5,000 shares of the Company's common stock to a newly hired employee of the Company as an inducement material to such employee's entry into employment with the Company, in accordance with Nasdaq Listing Rule 5635(c)(4) (the “Inducement Grant”).
CMP-002 administration resulted in a statistically significant improvement in seizure phenotypes and parameters in a SYNGAP1 haploinsufficient mouse model
CAMP4 Therapeutics Corporation (CAMP) came out with a quarterly loss of $0.32 per share versus the Zacks Consensus Estimate of a loss of $0.21. This compares to a loss of $0.62 per share a year ago.
Submitted first clinical trial regulatory filing for CMP-002 in Australia, with additional global regulatory filings planned in 2026; anticipates initiation of global Phase 1/2 clinical trial in SYNGAP1 patients in 2H 2026
Using epigenomic mapping and regulatory RNA (regRNA) Capture-seq, CAMP4 has assembled what it believes to be the largest catalog of regRNAs ever compiled, uncovering thousands of previously undiscovered regRNAs in human cells New research enables the discovery of antisense oligonucleotides (ASOs) to increase expression of disease-relevant genes for therapeutic potential CAMBRIDGE, Mass., April 28, 2026 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation (“CAMP4” or “the Company”) (Nasdaq: CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targeting therapeutics designed to upregulate gene expression with the goal of restoring healthy protein levels to treat a broad range of genetic diseases, today announced the submission of a preprint to bioRxiv, an open-access server for life sciences research, titled, “Profiling and Targeting of Regulatory RNAs to Upregulate Gene Expression.
Vancouver, British Columbia – TheNewswire - April 21, 2026 – Canadian GoldCamps Corp. (CSE: CAMP) (OTC: SMATF) (FSE: A68) (the “ Company ”) announces that, in connection with its previously announced non-brokered private placement (the " Offering ") on March 6, 2026, the Canadian Securities Exchange (the " CSE ") has approved an extension of the Company's price protection to June 5, 2026, in order to complete subscriptions. As previously disclosed, the Offering consists of up to 13,333,333 units of the Company (the " Units ") at a price of $0.15 per Unit for gross proceeds of up to $2,000,000. Each Unit will consist of one common share of the Company (a " Common Share ") and one-half of one common share purchase warrant (each whole warrant, a " Warrant "). Each Warrant will entitle the holder to acquire one additional Common Share at a price of $0.25 per share for a period of 24 months from the date of issuance.
CAMBRIDGE, Mass., April 17, 2026 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation (“CAMP4” or “the Company”) (Nasdaq: CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targeting therapeutics designed to upregulate gene expression with the goal of restoring healthy protein levels to treat a broad range of genetic diseases, today announced that on April 15, 2026 (the “Grant Date”), the Compensation Committee of the Company's Board of Directors granted non-qualified stock options to purchase an aggregate of 43,000 shares of the Company's common stock to three newly hired employees of the Company, each as an inducement material to such employee's entry into employment with the Company, in accordance with Nasdaq Listing Rule 5635(c)(4) (the “Inducement Grants”).
Vancouver, April 14, 2026 – TheNewswire – Canadian GoldCamps Corp. (CSE: CAMP) (OTC: SMATF) (FSE: A68) is pleased to provide a corporate update following the successful completion of its definitive mineral property option agreement (the “ Option Agreement ”) with Stelmine Canada Ltd. (“ Stelmine ”) (TSXV: STH) in respect of the Courcy and Mercator mineral projects located in Québec (the “ Projects ”). Following the execution of the Option Agreement, formalizing the Company's right to earn up to an 80% interest in the Projects, the Company is moving forward with the initial exploration campaign planning.
CAMBRIDGE, Mass., March 24, 2026 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation (“CAMP4” or “the Company”) (Nasdaq: CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targeting therapeutics designed to upregulate gene expression with the goal of restoring healthy protein levels to treat a broad range of genetic diseases, today announced the appointment of Michael MacLean to the Company's Board of Directors.
